作者
Qingqing Sang,Wentao Dai,Junxian Yu,Yunqin Chen,Zhiyuan Fan,Jixiang Liu,Fangyuan Li,Jianfang Li,Xiongyan Wu,Junyi Hou,Beiqin Yu,Haoran Feng,Zhenggang Zhu,Liping Su,Yuanyuan Li,Bingya Liu
摘要
Background: Increasing evidence has elucidated that tumor microenvironment (TME) shows a strong association with tumor progression and therapeutic outcome. The contributive roles of cellular interactions in the TME and the underlying molecular events need to be further investigated. Methods: We comprehensively estimated the TME infiltration patterns of 111 GC and 21 normal stomach mucosa samples based on bulk transcriptomic profiles using the xCell tool that accommodates 64 cell types, and obtained GC TME-subtypes with unsupervised hierarchical clustering. The expression data of TME-relevant genes were utilized to build a GC prognostic model - GC_Score by LASSO-Cox regression. Findings: GC could be classified into three subtypes, TME-Stromal, TME-Mix, and TME-Immune according to TME infiltration patterns inferred from transcriptomic profiles, which corresponded well to survival outcomes. GC prognostic model was formulated as GC_Score = (0.21* CTGF) + (0.08 * EFEMP1) - (0.17 * PI3) - (0.16 * SLC3A1). Among the three GC TME-subtypes, TME-Stomal displayed the worst prognosis and the highest GC_Score, while TME-Immune had the best prognosis and the lowest GC_Score. CTGF, the highest weighted gene in GC_Score, was found to be over-expressed in GC, and its higher expression was correlated with worse clinical outcomes. In addition, CTGF exhibited significant correlation with the abundance of Fibroblasts. CTGF has the potential to induce trans-differentiation of peritumoral fibroblasts (PTFs) to cancer-associated fibroblasts (CAFs). Interpretation: Beyond characterizing TME subtypes associated with clinical outcomes, we correlated TME infiltration to molecular features and explored their functional relevance, which helps to get a better understanding of carcinogenesis and therapeutic response, and provide novel strategies for tumor treatments. Funding Information: This work was supported by the National Natural Science Foundation of China (No. 81772509 and 82072605 to B Liu, No. 81871904 to ZG Zhu, No. 82003169 to HR Feng, No. 81871902 and No. 82072616 to L Su, No. 32000472 to W Dai, No. 81902393 to BQ Yu, and No. 32100531 to Y Chen), and Natural Science Foundation of Shanghai (No. 19ZR1431700 to BQ Yu). Declaration of Interests: The authors have declared that no competing interest exists. Ethics Approval Statement: All patients provided written informed consent (IC). This study was approved by Ruijin Hospital Ethics Committee, Shanghai Jiao Tong University School of Medicine, Approval No. 2017-6.